When Viruses Meet Fungi: Tackling the Enemies in Hematology

The association of invasive fungal infections (IFI) and viral infections has been described in patients with hematologic malignancies (HM), in particular in hematopoietic stem cell transplant recipients. Regrettably, the diagnosis is often challenging, making the treatment inappropriate in some circumstances. The present review takes into consideration the viral infections commonly associated with IFI. Clinical presentation of IFI and viral infections, risk factors, and impact on the outcome of HM patients are discussed throughout the paper.

[1]  J. Gribben,et al.  Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients , 2020, British journal of haematology.

[2]  R. Ozaras,et al.  COVID-19-associated mucormycosis: Case report and systematic review , 2021, Travel Medicine and Infectious Disease.

[3]  P. Martín-Dávila,et al.  Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study , 2021, Journal of Infection.

[4]  M. Cheung,et al.  Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients , 2021, Blood Advances.

[5]  S. Joshi,et al.  Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[6]  T. Kuno,et al.  Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis: A systematic review and meta‐analysis , 2021, Mycoses.

[7]  M. Chiurlo,et al.  Invasive fungal infections in patients with COVID-19: a review on pathogenesis, epidemiology, clinical features, treatment, and outcomes. , 2021, The new microbiologica.

[8]  J. Baddley.  COVID-19 Associated Pulmonary Aspergillosis: Do We Have the CAPAcity to Improve Outcomes? , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  G. Gorkiewicz,et al.  Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy , 2021, Journal of fungi.

[10]  M. Perales,et al.  Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study , 2021, The Lancet Haematology.

[11]  O. Stötzer,et al.  Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study , 2021, Acta oncologica.

[12]  L. Millon,et al.  Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient , 2021, Infectious Diseases Now.

[13]  J. Perfect,et al.  Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance , 2020, The Lancet Infectious Diseases.

[14]  M. Netea,et al.  COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? , 2020, Journal of fungi.

[15]  H. Badali,et al.  Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran , 2020, Mycopathologia.

[16]  D. Farmakiotis,et al.  Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature , 2020, Diagnostics.

[17]  F. Fagioli,et al.  Successfully treated severe COVID‐19 and invasive aspergillosis in early hematopoietic cell transplantation setting , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[18]  C. de Ciuceis,et al.  Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID‐19 , 2020, Cancer.

[19]  V. Jiménez‐Yuste,et al.  Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study , 2020, Journal of Hematology & Oncology.

[20]  Yadan Wang,et al.  Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies , 2020, Leukemia & lymphoma.

[21]  G. Corrao,et al.  Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.

[22]  I. Falces-Romero,et al.  Isolation of Aspergillus spp. in respiratory samples of patients with COVID‐19 in a Spanish Tertiary Care Hospital , 2020, Mycoses.

[23]  K. Simon,et al.  Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit – High mortality rate in infected patients with haematologic malignancies , 2020, Journal of Clinical Virology.

[24]  J. Aguado,et al.  Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies , 2020, European journal of haematology.

[25]  T. Rogers,et al.  Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: A lethal combination , 2020, Medical Mycology Case Reports.

[26]  H. Nakasone,et al.  Association between the kinetics of cytomegalovirus reactivation evaluated in terms of the area under the curve of cytomegalovirus antigenemia and invasive mold infection during the post‐engraftment phase after allogeneic hematopoietic stem cell transplantation , 2020, Transplant infectious disease : an official journal of the Transplantation Society.

[27]  M. Hoenigl,et al.  COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment , 2020, Journal of fungi.

[28]  N. Van Regenmortel,et al.  COVID-19-associated invasive pulmonary aspergillosis , 2020, Annals of Intensive Care.

[29]  B. Mégarbane,et al.  Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19 , 2020, The Lancet Respiratory Medicine.

[30]  M. Labopin,et al.  COVID-19 outcomes in patients with hematologic disease , 2020, Bone Marrow Transplantation.

[31]  S. Kalnicki,et al.  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.

[32]  R. Piarroux,et al.  Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient , 2020, Emerging infectious diseases.

[33]  M. Hallek,et al.  COVID‐19 associated pulmonary aspergillosis , 2020, Mycoses.

[34]  B. Rijnders,et al.  Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination? , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  C. Solano,et al.  Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients , 2019, Transplant infectious disease : an official journal of the Transplantation Society.

[36]  T. van der Poll,et al.  Detection of Invasive Aspergillosis in Critically Ill Patients with Influenza: the Role of Plasma Galactomannan. , 2019, American journal of respiratory and critical care medicine.

[37]  H. Einsele,et al.  Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). , 2019, The Lancet. Infectious diseases.

[38]  D. Kontoyiannis,et al.  Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study , 2019, Open forum infectious diseases.

[39]  A. Freifeld,et al.  Epidemiology, Diagnosis, Treatment, and Prevention of Influenza Infection in Oncology Patients. , 2019, Journal of oncology practice.

[40]  Yi Zhang,et al.  Invasive pulmonary aspergillosis in patients with influenza infection: A retrospective study and review of the literature , 2019, The clinical respiratory journal.

[41]  L. Strasfeld,et al.  Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient , 2019, Infectious Disease Clinics of North America.

[42]  A. Ceribelli,et al.  Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship? , 2019, International journal of molecular sciences.

[43]  C. Breynaert,et al.  Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment , 2018, Current opinion in infectious diseases.

[44]  D. Kontoyiannis,et al.  Invasive fungal disease and cytomegalovirus infection: is there an association? , 2018, Current opinion in infectious diseases.

[45]  M. Sohail,et al.  Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts , 2018, Infection.

[46]  F. Ensoli,et al.  Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant , 2018, Hematological oncology.

[47]  E. Tuomanen,et al.  A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients , 2017, Journal of the Pediatric Infectious Diseases Society.

[48]  M. Mizuguchi,et al.  Human Parainfluenza Virus Type 3 Infections in Patients with Hematopoietic Stem Cell Transplants: the Mode of Nosocomial Infections and Prognosis. , 2018, Japanese journal of infectious diseases.

[49]  Michael Boeckh,et al.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation , 2017, The New England journal of medicine.

[50]  S. Lewin,et al.  Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[51]  L. Danziger-Isakov,et al.  Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation , 2017, Clinics in Chest Medicine.

[52]  Y. Chuang,et al.  Higher mortality of severe influenza patients with probable aspergillosis than those with and without other coinfections. , 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

[53]  L. Pagano,et al.  Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. , 2017, Blood reviews.

[54]  R. Larson,et al.  Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment , 2016, Leukemia & lymphoma.

[55]  A. Deol,et al.  Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab , 2016, Annals of Hematology.

[56]  M. Sorror,et al.  CMV Viral Load and Mortality after Hematopoietic Cell Transplantation: A Cohort Study in the Era of Preemptive Therapy , 2016, The Lancet. Haematology.

[57]  F. Ensoli,et al.  Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. , 2016, The Journal of infection.

[58]  M. Yigla,et al.  Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome , 2016, Infection.

[59]  T. Nakazato,et al.  Cytomegalovirus reactivation in patients with multiple myeloma , 2016, European Journal of Haematology.

[60]  E. Urbán,et al.  Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study , 2016, Annals of Hematology.

[61]  He Huang,et al.  Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years , 2015, Journal of Zhejiang University-SCIENCE B.

[62]  M. Saad,et al.  Cytomegalovirus Reactivation in Adult Recipients of Autologous Stem Cell Transplantation: a Single Center Experience , 2015, Mediterranean journal of hematology and infectious diseases.

[63]  M. Boeckh,et al.  Clinical Outcomes Associated With Respiratory Virus Detection Before Allogeneic Hematopoietic Stem Cell Transplant , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  Â. Maiolino,et al.  Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[65]  G. Papanicolaou,et al.  Valganciclovir for the Prevention of Complications of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation , 2015, Annals of Internal Medicine.

[66]  M. Maschio,et al.  Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single‐institution study , 2014, Transplant infectious disease : an official journal of the Transplantation Society.

[67]  P. Chiusolo,et al.  Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[68]  H. Einsele,et al.  Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. , 2014, The New England journal of medicine.

[69]  I. Benet,et al.  An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting , 2014, Journal of medical virology.

[70]  Russell E. Lewis,et al.  A Risk Prediction Score for Invasive Mold Disease in Patients with Hematological Malignancies , 2013, PloS one.

[71]  G. Papanicolaou,et al.  CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. , 2013, The New England journal of medicine.

[72]  Mehul R. Patel,et al.  Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: a retrospective cohort study , 2013, Leukemia & lymphoma.

[73]  W. Leisenring,et al.  Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients , 2013, Biology of Blood and Marrow Transplantation.

[74]  G. Tricot,et al.  Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[75]  J. Wagner,et al.  Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[76]  G. Avvisati,et al.  The potential role of pre‐transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network , 2012, American journal of hematology.

[77]  Jianmin Yang,et al.  Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: A single center study of 190 recipients , 2012, Scandinavian journal of infectious diseases.

[78]  Kevin Shiley,et al.  CT of viral lower respiratory tract infections in adults: comparison among viral organisms and between viral and bacterial infections. , 2011, AJR. American journal of roentgenology.

[79]  C. Renaud,et al.  Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients , 2011, Current opinion in infectious diseases.

[80]  H. Einsele,et al.  Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. , 2011, The Lancet. Infectious diseases.

[81]  M. Boeckh,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients. , 2011, Hematology/oncology clinics of North America.

[82]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[83]  L. Qiu,et al.  Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single‐institution experience , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[84]  R. Foà,et al.  Prospective cytomegalovirus monitoring during first‐line chemotherapy in patients with acute myeloid leukemia , 2010, Journal of medical virology.

[85]  A. Wald,et al.  Respiratory Virus Pneumonia after Hematopoietic Cell Transplantation (HCT): Associations between Viral Load in Bronchoalveolar Lavage Samples, Viral RNA Detection in Serum Samples, and Clinical Outcomes of HCT , 2010, The Journal of infectious diseases.

[86]  V. V. Van Deerlin,et al.  Chest CT Features of Community-acquired Respiratory Viral Infections in Adult Inpatients With Lower Respiratory Tract Infections , 2010, Journal of thoracic imaging.

[87]  J. Rossen,et al.  Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes , 2010, Biology of Blood and Marrow Transplantation.

[88]  A. Ibatici,et al.  Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients , 2009, Bone Marrow Transplantation.

[89]  J. Briones,et al.  Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT , 2009, Bone Marrow Transplantation.

[90]  A. Simon,et al.  Low prevalence of human metapneumovirus and human bocavirus in adult immunocompromised high risk patients suspected to suffer from Pneumocystis pneumonia , 2009, Journal of Infection.

[91]  L. Leng,et al.  Human Cytomegalovirus Paralyzes Macrophage Motility through Down-Regulation of Chemokine Receptors, Reorganization of the Cytoskeleton, and Release of Macrophage Migration Inhibitory Factor1 , 2009, The Journal of Immunology.

[92]  K. Marr,et al.  Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[93]  J. Sierra,et al.  Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies , 2007, American journal of hematology.

[94]  N. Müller,et al.  Viral Pneumonia After Hematopoietic Stem Cell Transplantation: High-Resolution CT Findings , 2007, Journal of thoracic imaging.

[95]  H. Einsele,et al.  Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantati , 2006, Blood.

[96]  Alberto Hidalgo,et al.  Thin-section CT findings in hematopoietic stem cell transplantation recipients with respiratory virus pneumonia. , 2006, AJR. American journal of roentgenology.

[97]  J. Sierra,et al.  Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[98]  M. Maris,et al.  Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. , 2003, Blood.

[99]  M. Boeckh,et al.  Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[100]  N. Russell,et al.  Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation , 2001, Bone Marrow Transplantation.